SCHEMBL30795406

SCHEMBL30795406

COCCn1c(=O)c(C(=O)NCc2cccc(F)c2)c(C)c2ccc(C(F)(F)F)cc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 2/20 0.46
PDE10A Q9Y233 1/20 0.44
CCR1 P32246 3/20 0.42
MAPT P10636 2/20 0.41
ALDH1A1 P00352 3/20 0.41
GAA P10253 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GLA P06280 1/20 0.41
PPARG P37231 1/20 0.41
NPC1 O15118 1/20 0.41
POLB P06746 1/20 0.41
RAB9A P51151 1/20 0.41
ROCK2 O75116 1/20 0.41
MLYCD O95822 1/20 0.40
GLS O94925 1/20 0.40
HPGD P15428 1/20 0.40
ALOX12 P18054 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29501 1.00 S1PR3 (0.46) S1PR3PDE10ACCR1MAPTALDH1A1
SCHEMBL29084 0.95 S1PR3 (0.43) S1PR3PDE10ACCR1MAPTALDH1A1
SCHEMBL30795901 0.95 S1PR3 (0.43) S1PR3PDE10ACCR1MAPTALDH1A1
SCHEMBL29862 0.95 S1PR3 (0.45) S1PR3PDE10ACCR1MAPTALDH1A1
SCHEMBL30794729 0.95 S1PR3 (0.45) S1PR3PDE10ACCR1MAPTALDH1A1
SCHEMBL29970 0.93 S1PR3 (0.48) S1PR3PDE10ACCR1MAPTALDH1A1
SCHEMBL30795971 0.93 S1PR3 (0.48) S1PR3PDE10ACCR1MAPTALDH1A1
SCHEMBL714174 0.92 S1PR3 (0.45) S1PR3PDE10ACCR1MAPTALDH1A1
SCHEMBL29002 0.91 S1PR3 (0.45) S1PR3PDE10ACCR1MAPTROCK2
SCHEMBL30795738 0.91 S1PR3 (0.47) S1PR3PDE10ACCR1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed